GCT has established clinical operations in three new countries: Hungary, Czech Republic and Slovakia. In these countries GCT now offers its clients full assistance for clinical trials, including feasibility studies, clinical monitoring, project management, regulatory support.
CEE region is known in the biopharma sector as an advantageous destination to place clinical trials. Compliant and motivated patient population, highly skilled and trained investigators, centralized healthcare system – all these factors contribute to fast patient enrollment and steady retention rates. Combined with the short regulatory timeline, they constitute the reasons to use the opportunities this region offers.
By spreading the geographical coverage, GCT gains the position to offer its clients a more extensive range of services and utilize all benefits of the region.
Dr. Eugene Selivra, Chief Executive Officer of GCT stated: «The expansion of GCT operations to Hungary, Czech Republic and Slovakia will allow us to increase our capabilities in key areas that align with current and future growth plans. These Central European countries are a perfect addition to our existing locations in both cultural and operational sense. We feel that this step will strengthen our ability to deliver high-quality clinical development services to our existing and new Sponsors.”
Ms. Csilla Leka, MSc. has been appointed by GCT executives to provide oversight and management of clinical operations in Hungary, Czech Republic and Slovakia. Csilla will be based in Budapest office. She joins GCT with 6-year experience as project leader in a European CRO, having accumulated the knowledge of on-site monitoring activities, financial and management aspects of clinical trials.